Why Neurocrine Biosciences, Inc.’s (NBIX) Stock Is Up 13.27%
As of Tuesday, November 03, Neurocrine Biosciences, Inc.’s NBIX share price has surged by 13.27%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: Neurocrine Biosciences, Inc. (NBIX)
Neurocrine Biosciences, Inc. NBIX
$164.63
4.87
3.05%
November 6, 2026 4:00:00 PM
EST
Volume: 1,507,458
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Commentary & Analysis
What You Need to Know About Neurocrine Biosciences, Inc.'s Q4 Earnings
Neurocrine Biosciences, Inc.'s fiscal Q4 earnings report was released on Monday, November 02. Let's dive in to see if (NBIX) missed or beat analyst's expectations.Jenna Brashear
Which Is a Better Investment, Kymera Therapeutics, Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Kymera Therapeutics, Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, Neurocrine Biosciences, Inc. or BeOne Medicines AG Stock?
Learn more about whether Neurocrine Biosciences, Inc. or BeOne Medicines AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, Neurocrine Biosciences, Inc. or BeOne Medicines AG Stock?
Learn more about whether Neurocrine Biosciences, Inc. or BeOne Medicines AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Financial Summary
| Share Statistics | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $16,170.7 | $214.3 | 84% |
|
| Shares Out (Mil) | 105.2 | 53.9 | 63% |
|
| Institutional Ownership | 98.8% | 92.9% | 82% |
|
| Float (Mil) | 99.9 | 41.4 | 60% |
|
| Beta | 0.33 | 0.96 | 19% |
|
| Avg Daily Volume (000s) | 1,657 | 506 | 77% |
|
| Price Change (52-week) |
11.6% | 43.9% | 61% |
|
| Growth | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.3% | 13.2% | 84% |
|
| Net Income (5yr) | 3.3% | (10.1%) | 45% |
|
| EPS (5yr) | 2.3% | 15.8% | 35 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 43.2% | (15.7%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 15 | 14 | 15 | |
| Current EPS | $2.794 | $10.317 | $11.973 | |
| Month Ago EPS | $2.835 | $10.214 | $11.877 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $2.826 | $10.170 | $12.173 | |
| Year/Year Chg | 42.6% | 120.9% | 234.0% | |
| Financials | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,702 | $37 | 70% |
|
| Net Income (TTM) (Mil) | $703 | ($44) | 82% |
|
| EPS (TTM) | $6.971 | ($1.500) | 90% |
|
| Operating Cash Flow (TTM) (Mil) | $1,066 | ($34) | 81% |
|
| Net Cash Flow (TTM) (Mil) | $300 | $1 | 87% |
|
| Long-Term Debt (Q1) (Mil) | $392 | $4 | 56% |
|
| Enterprise Value (Q1) (Mil) | $16,471 | $172 | 81% |
|
| Valuation | NBIX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.17 | 2.00 | 77% |
|
| P/E | 23.7 | 18.5 | 62% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 10.3 | 0.9 | 94% |
|
| Ratios | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.7% | 67.3% | 77% |
|
| Net Margin | 19.0% | (63.5%) | 77% |
|
| ROA | 14.2% | (47.5%) | 92% |
|
| ROE | 20.4% | (53.3%) | 80% |
|
| Liabilities to Assets | 31.1% | 29.6% | 22% |
|
| F-Score | 7 | 2 | 82% |
|
Neurocrine Biosciences, Inc. did not pass any screens on 11/5/2026.
